Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...

Shares of the Australia-based CSL Ltd. (AU:CSL) fell by over 4% as of writing despite the company achieving higher profit in FY24. The company reported an NPAT (net profit after tax) attributable to ...

I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine ("Seqirus") and plasma therapy ("Behring") segments. Seqirus is witnessing revenue declines as a result of ...

Earnings call CSL reported H1 FY26 revenue of $8.3B (down 4% YoY, constant currency) and NPATA of $1.9B (down 7%). Reported NPAT fell 81% due to $1.05B in impairments. Despite challenges, full-year ...

CSLLY's FY 2024 results were good thanks to the outperformance of the Behring segment; the company's net profit in constant currency terms grew +15% YoY to $2.91 billion, which was in line with ...

As investors, we’re irresistibly drawn to milestones, and the past year has provided a jackpot of them. The ASX stormed past 8,000, Bitcoin soared beyond US$100,000, NVIDIA hit a mind-boggling US$3 ...

Shares down 3.3%, face worst day since mid-Feb FY25 NPAT forecast below Visible Alpha consensus Final dividend of $1.45/share vs last year's $1.29 Aug 13 (Reuters) - Shares of CSL Ltd (CSL.AX), opens ...

CSL Ltd (ASX: CSL) shares can't escape the wider market sell-down today. Shares in the S&P/ASX 200 Index (ASX: XJO) biotech ...

CSL to downsize one-third of R&D division, AFR reports Company has not confirmed the number of job reductions Shares up 3% at over 6-week high July 15 (Reuters) - Australian biotech giant CSL Ltd (CSL ...